The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Open accessAbstract
Purpose: Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC. Patients and Methods: Patients were randomly assigned to IP (irinotecan 60 mg/m 2 on days 1, 8, and 15; cisplatin 60 mg/m 2 day 1, every 4 weeks) or EP (etoposide 100 mg/m 2 on days 1 through 3; cisplatin 80 mg/m 2 day 1, every 3 weeks). Blood specimens for genomic DNA analysis were collected before random assignment in 169 patients. Results: Of 671 patients, 651 were eligible (324 and 327 patients in the IP and EP arms, respectively). Response rates with IP and EP were 60% and 57%, respectively (P = .56). Median progression-free survival for IP and EP was 5.8 and 5.2 months, respectively (P = .07). Median overall survival for IP and EP was 9.9 and 9.1 months, respectively (P = .71). Severe diarrhea was more common with IP (19% v 3%); severe neutropenia and thrombocytopenia were higher with EP versus IP (68% v 33% and 15% v 4%, respectively). PG analysis showed that ABCB1 (C3435T)T/T (membrane transport) was associated with IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutropenia. Conclusion: This large North American trial failed to confirm the previously reported survival benefit observed with IP in Japanese patients. Both regimens produced comparable efficacy, with less hematologic and greater gastrointestinal toxicity with IP. These results emphasize the potential importance of PG in interpreting trials of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Hanna, N., Bunn, P. A., Langer, C., Einhorn, L., Guthrie, T., Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8595 · Cited by 681
Self-citationMishima, S., Nozaki, Y., Mikami, S., Kihira, E., Iikura, M., Koketsu, R., Sugiyama, H., Masuda, T., Kaname, H., Egami, Y., et al. (2015) · Case Reports in Gastroenterology · doi:10.1159/000381140 · Cited by 631
Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1563 · Cited by 381
Self-citationTrends in the globalization of clinical trials
Thiers, F. A., Sinskey, A. J., & Berndt, E. R. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2441 · Cited by 355
Schiller, J. H., Adak, S., Cella, D., DeVore, R. F., & Johnson, D. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2114 · Cited by 294
de Jong, F. A., Marsh, S., Mathijssen, R. H. J., King, C., Verweij, J., Sparreboom, A., & McLeod, H. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0144 · Cited by 207
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Small cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., & Felip, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt178 · Cited by 613
Garcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., Sedlackova, E., Toumpanakis, C., Anlauf, M., Cwikla, J. B., et al. (2016) · Neuroendocrinology · doi:10.1159/000443172 · Cited by 611
Metadata
- Authors
- Lara, P. N., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., Chansky, K., & Gandara, D. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-05-20
- Volume
- 27
- Issue
- 15
- Pages
- 2530-2535
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170260373
- Cited by
- 525
- References
- 18
- FWCI
- 18.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124. https://app.cochat.ai/papers/10.1200/jco.2008.20.1061
- The paper
- Lara, P. N., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., Chansky, K., & Gandara, D. R. (2009). Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.20.1061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.